Detailed explanation of usage and dosage of cabotegravir/rilpivirine injection suspension

Cabotegravir/rilpivirine injection suspension (cabotegravir and rilpivirine) , as an innovative long-acting injection solution, is specially designed for adults and adolescents 12 years old and above HIV-1 virus infection. The drug consists of two active ingredients: cabotegravir and rilpivirine, which are HIV-1 integrase strand transfer inhibitors and non-nucleoside reverse transcriptase inhibitors respectively, providing a new option for HIV treatment.

When using cabotegravir/rilpivirine injection suspension, patients can choose oral introduction or direct injection treatment. If you choose oral introduction, you need to take 30 mg of cabotegravir and 25 mg of rilpivirine orally with food every day for at least 28 consecutive days to prepare for subsequent injection treatment.

For the monthly dosing schedule, patients will receive injections into the gluteal muscle after completing the oral induction. The initial dose of cabotegravir is 600 mg, with subsequent monthly doses of 400 mg; the initial dose of rilpivirine is 900 mg, with subsequent monthly doses of 600 mg. For the every 2 monthly dosing schedule, patients will receive cabotegravir at the 1 month and the 2 month after oral introduction for at least 28 days. 600mg and rilpivirine 900mg injections, starting from the 4 month, once every 2 months, the dose is the same as the initial dose.

In terms of storage, cabotegravir/rilpivirine injection suspension should be placed in the original carton and stored in a refrigerator at 2-8℃ to ensure the stability and effectiveness of the drug. Do not freeze this product as it may lose effectiveness. At the same time, do not mix the drug with any other drugs or diluents to avoid affecting the efficacy and safety of the drug.

The vial should be brought to room temperature (not exceeding25°C) and kept in the carton for up to 6 before administration.Hour. If not used within 6 hours, it must be discarded. Once the suspended drug has been drawn into the corresponding syringe, it should be injected as soon as possible but should only remain in the syringe for up to 2 hours. If more than 2 hours have passed, the medication, syringe, and needle must be discarded to ensure the safety and hygiene of the injection process.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212888s011lbl.pdf